Clinical Trials Directory

This study has two groups based on a test called the Signatera test. People in Group A have a positive test. They will be placed by chance into one of two treatment groups. One group will get a medicine called nivolumab. The other group will get two medicines, nivolumab and relatlimab. These medicines are given through a vein once every 28 days, and people can get up to 12 cycles. People in Group B have a negative test. They will be placed by chance into one of two choices. One choice is to get nivolumab right away, given through a vein once every 28 days for up to 12 cycles. The other choice is close monitoring without starting medicine right away. If their Signatera test changes from negative to positive, they will then be offered nivolumab for up to 12 cycles.

We are doing this study to find the most effective, safe dose of an experimental drug called xaluritamig (the study drug). We want to know how well this drug works compared to the standard drugs for people who have metastatic castration-resistant prostate cancer.

We are doing this study to compare how safe and effective different drug combinations are for treating metastatic cancer.

We are doing this study to find the most effective, safe dose of a combination of the drugs fianlimab and ceminplimab. We want to know if this combination is an option for people with melanoma. We will compare how well this drug combination works to the usual treatment of relatlimab and nivolumab, which has the brand name Opdualag®.

We are doing this study to find out if an experimental drug called APL-5125 (the study drug) is a safe and effective for people with select types of gastrointestinal cancer. We are also trying to find the best dose of APL-5125 to use.

We are doing this study to find out if a study drug called sacituzumab govitecan can improve outcomes for patients with high risk, early triple negative breast cancer (TNBC). We want to know if giving this drug in combination with pembrolizumab will work better than pembrolizumab on its own or better than pembrolizumab + capecitabine.